Trial Profile

Tolerability outcomes of NVC 422 administered as a bladder and catheter lavage solution in volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Auriclosene (Primary)
Indications Bacterial infections; Catheter infections; Urinary tract infections
Focus Adverse reactions
Sponsors NovaBay Pharmaceuticals; Stablecoin Development Corporation

Most Recent Events

23 Mar 2026 According to a Stablecoin Development Corporation media release, NovaBay Pharmaceuticals is now called Stablecoin Development Corporation.
02 Feb 2011 Planned number of patients changed to 32, according to a media release from NovaBay Pharmaceuticals.
14 May 2008 Status changed from in progress to completed, according to a NovaBay media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com